Lupus nephritis: A clinical review for practicing nephrologists

Clinical Nephrology

Volumn 57, Issue 2, 2002, Pages 95-107

  Contreras, G ^a   Roth, D ^a   Pardo, V ^a   Striker, L G ^a   Schultz, D R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppressive agents; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

5,8,11,14,17 ICOSAPENTAENOIC ACID; ANCROD; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID; THROMBOXANE RECEPTOR BLOCKING AGENT; THROMBOXANE SYNTHASE INHIBITOR;

AMENORRHEA; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; NEPHRITIS; NEPHROLOGY; NEPHROTIC SYNDROME; NONHUMAN; PROGNOSIS; PROLIFERATIVE GLOMERULONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING; URINALYSIS;

EID: 0036167171     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP57095     Document Type: Review

References (48)

1. Long-term follow-up of lupus nephritis: A study based on the WHO classification
2. Evidence for the presence of antibodies to the collagen-like region of C1q in systemic lupus erythematosus
3. Natural history and treatment of lupus nephritis
4. High-risk features of lupus nephritis: Importance of race and clinical and histologic factors in 166 patients
5. Prognostic factors in lupus nephritis, contribution of renal histologic data
6. Treatment of lupus nephritis: A meta-analysis of clinical trials
7. Lupus nephritis: Nephrology forum
8. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis
9. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
10. Hereditary C1q deficiency and systemic lupus erythematosus
11. Lupus nephritis
12. A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus
13. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
14. Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone
15. Lupus nephritis, lupus-like syndrome, and antiphospholipid antibody syndrome
16. Immunosuppressive therapy for proliferative lupus nephritis: Preliminary report of a prospective, randomized clinical trial with mycophenolate mofetil
17. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus
18. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease
19. Lupus nephritis
20. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
21. The clinical and renal biospy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature
22. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice
23. A randomized trial of plasmapheresis and subsequent pulse cyclosphosphamide in severe lupus: Design of the LFSG trial
24. Leukotriene B4 in inflammation
25. Antibodies to DNA
26. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus
27. ARA criteria. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
28. Aspiration biopsy of the kidney
29. Study of renal complications of disseminated lupus erythematosus: Report of four cases
30. Systemic lupus erythematosus
31. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Result of treatment with prednisone and short-term oral cyclosphosphamide
32. A controlled trial of plasmapheresis therapy in severe lupus nephritis
33. End-stage renal disease and systemic lupus erythematosus
34. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis
35. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders
36. On the visceral complications of erythema exudativum multiforme
37. Lupus membranous nephropathy: Long-term outcome
38. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status
39. The natural history of the renal manifestations of systemic lupus erythematosus
40. Lupus membranous nephropathy (LMN): Course and prognosis in 50 patients
41. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus
42. Homozygous hereditary C1q and systemic lupus erythematosus. A new family and the molecular basis of C1q deficiency in three families
43. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis
44. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only
45. The 1982 revised criteria for the classification of systemic lupus erythematosus
46. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus (SLE)
47. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus
48. Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis